September 20th Biotech Update

Still a boring market in terms of news. The sector appears to have successfully defended the bottom end of its range but one could argue it done so simply by.

September 18 Biotech Update

The sector struggled yesterday and it still looks like testing the bottom on the range is possible. Perhaps the China tariffs news cleared the market a little and we might.

XENE Pipeline Keep Growing – Is XEN007 The Next Surprise?

Last week, Xenon pharmaceuticals (XENE) passed one of the most important tests in the stock market, where the share price closed on Friday at $14.05, above the $14.03 resistance line,.

September 17 Biotech Update

Not a great start to the week in terms of trading as it looks like we are set to retest the bottom on the range (yet again). As long as.

SRPT’s CEO Fireside Chat at Morgan Stanley Conference

Sarepta (SRPT) had a great run last week, a kick off following MS fireside chat, closing at $152.76 the highest “close” since June 21st (highest 52W close 06/20 was $153.69).

September 13th Biotech Update

We are finally getting a broad snap back rally but it needs to be more than a simple morning rally that is faded as the day goes along. If this.

September 12th Biotech Update

The sector is certainly struggling and its inability to generate any consistent buying interest after the sell-off is certainly worrisome. All of that being said there are so many names.

September 11th Biotech Update

While we have another snoozer of a day in biotech land, it does provide some insight into the trading bias of the sector and it remains negative. You would think.

September 10 Biotech Update

There is nothing going on in the sector. No real news. No new deals. You would have thought that September would bring about some news but it seems like we.

September 5 Biotech Update

The hurricane thankfully missed us, so back in the office. The sector had a rough day yesterday but it only took us to the area that should act as new.

September 4 Biotech Update

Another slow start to the week. Sometimes there are expectations for deals after long weekends but the sector continues to disappoint in terms of M&A. Given how important M&A was.

August 30th Biotech Update

The range finally seems broken and pretty decisively to the upside. The sector is not just moving higher but it is outperforming the broader market on a relative basis. Given.

XENE – Quick note, Positive TMS Data Presented at The European Congress on Epileptology

Today morning, Xenon Pharmaceutical (XENE) reported positive data from its XEN1101 Phase 1b transcranial magnetic stimulation (TMS) study. (LINK) XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as.

August 28th Biotech Update

We got off to a good start yesterday and there is perhaps some early follow through this morning but not much. We are inching closer to the upper end of.

August 27 Biotech Update

A good start to the week both in having news to talk about and the price action. While it is easy to get excited about good price action, we remain.

August 24th biotech update

The snoozer of a week continues with the sector still chopping in its range. Perhaps next week we wake up a little but odds are we are stuck in this.

August 22nd Biotech Update

Still not a ton of news and the sector moved higher with the market taking it a little further from the edge but still well within its range. I am.

Dave Trading – August 2018

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

August 20 Biotech Update

I understand that it is still the summer but this is an absolutely no news start to the week. We remain in a choppy market until proven otherwise and this.

August 17th Biotech Update

Up, down, up, down, and repeat. Yesterday was green so today is most likely to be red. While it is difficult to discern a trend in such a low volume,.

August 16th Biotech Update

The sector was pretty weak yesterday but remained in its range. While there is nothing to dissuade me from the summer chop, there are some warning signs. First, we are.

August 15th Biotech Update

A pretty weak open for the sector but again this is nothing more than low volume chop as I see it. Unless it breaks below 113 on the IBB and.

Bellus – David vs. Goliath Can BLU Deliver A Better Chronic Cough Drug Than Merck?

BELLUS Health (BLU.TO) (BLUSF) is a biopharmaceutical development company based in Quebec, Canada, its pipeline includes several partnered clinical-stage drug development programs, but the company’s lead drug candidate is BLU-5937.

August 13 Biotech Update

The chop continues and I suspect this week will be no different. There is not any news to start the week that would excite or disappoint, which means the previous.

August 10th Biotech Update

While yesterday ended up being quite positive for the sector (in general), I am still not going to read too much into it and would not be surprised to see.

August 9th Biotech Update

The chop continues. I just do not see anything definitive in either direction and am coming around to the belief that we are not going to see anything definitive soon..

XENE – Quick note, Q2 Earnings and Epilepsy Long Term Value Creation

Follow up to my previous report “XENE – Epilepsy and Advocacy Under the New FDA” (Link) XENE released their Q2 earning report and hosted a conference call and webcast to.

August 8th Biotech Update

We are not quite getting the clarity to the upside but there is nothing to indicate that the sector is about to break to the downside. It seems like the.

XENE – Epilepsy and Advocacy Under the New FDA

Xenon Pharmaceuticals (XENE) is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for neurological disorders. XENE has an extensive knowledge of human genetics and diseases caused.

August 6 Biotech Update

A slow start to the week in which there are a lot of earnings calls but likely nothing to change the course of the sector. That has already been set.

August 3 Biotech Update

I will quickly finish up the week as there are a couple of interesting tidbits and the broader trading is more or less the same. There are some areas of.

Browsing 31 / 3 articles